Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Estimated distribution of the incremental cost-effectiveness ratio of risk stratification with MTWA testing versus medical therapy in the MADIT-II–eligible population. Data were obtained by performing 10,000 Monte Carlo simulations. The cost-effectiveness ratio was less than $50,000/QALY in 5,459 (54.6%) of the simulations, whereas none of the simulations yielded cost-effectiveness ratios above $100,000/QALY. Abbreviations as in Figures 1 and 2.
|
